Albany Molecular Research (AMRI) has purchased all the outstanding shares of Spain-based Gadea Pharmaceutical Group for around $174m.

Under the deal, AMRI has agreed to issue of 2.2 million shares of common stock worth about $43.8m to Gadea’s owners.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

AMRI president and CEO William Marth said: "The acquisition of Gadea marks another milestone in our company’s path towards becoming the pre-eminent supplier of custom and complex drug development services and product to both the branded and generic pharmaceutical industry.

Based in Valladolid, Gadea Pharmaceutical Group is an independent Spanish firm that includes Crystal Pharma, Cyndea Pharma and Gadea Biopharma.

"Gadea operates active pharmaceutical ingredients (API) business and finished dose development and manufacturing business and reported $83m in revenue in 2014."

The group operates active pharmaceutical ingredients (API) business and finished dose development and manufacturing business and reported $83m in revenue in 2014.

Gadea’s Crystal Pharma is expected to expand AMRI’s API portfolio, allowing the firm to become a source of specialty and generic API.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Crystal Pharma is involved in large-scale commercial API production, specialising in steroids, high-potency hormones, and sterile steroids.

Crystal’s API portfolio comprises 22 active US drug master files (DMFs), 17 EU certificate of suitability (COSs), 13 Japanese DMFs and two South Korean DMFs.

Gadea CEO Gerardo Gutierrez said: "Our capabilities in technically challenging API and diverse customer base are highly complementary to AMRI."

The acquisition will also expand AMRI’s API development and manufacturing capabilities in steroids and hormones.

The acquired business also enhances firm’s sterile drug product offerings with the addition of ophthalmic and parenteral suspension dosage forms and prefilled syringe and lyophilisation capability.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact